Loading clinical trials...

Validation of a Semi-automatized Method to Detect Cyclic Hyperinflation on CT-scan in ARDS | Clinical Trials | Clareo Health

COMPLETEDNA

Validation of a Semi-automatized Method to Detect Cyclic Hyperinflation on CT-scan in ARDS

NCT03870009•Hospices Civils de Lyon

View on ClinicalTrials.gov

Summary

This study aims to validate a semi-automatized method to quantify cyclic hyperinflation on CT-scan of ARDS patients. The gold standard will be cyclic hyperinflation assessed on the same CT scan, using manual segmentation of the lung.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•ARDS patients defined by the Berlin definition
•invasive mechanical ventilation with an arterial oxygen pressure (PaO2)/inspired fraction of oxygen (FiO2) ratio ≤ 200 mm Hg
•Indication of CT scan identified by the clinician in charge
•oesophageal catheter already inserted

Exclusion Criteria

•requirement of contrast agent for a chest CT-scan
•ARDS criteria present for more than 72 hours
•Chronic Obstructive Pulmonary Disease (COPD) on a previous lung function test
•pneumothorax or bronchopleural fistula
•patient without both sedation and neuromuscular blocking agents
•contra-indication to transport to the imaging facility
•treatment with extracorporeal membrane oxygenation or extracorporeal carbon dioxide (CO2) removal
•Latex or curare allergy
•patient previously included in the study
•pregnancy
+5 more criteria

Locations (1)

Croix Rousse Hospital

Lyon, France

Key Dates

Start Date

May 21, 2019

Primary Completion Date

February 16, 2021

Completion Date

February 16, 2021

Last Updated

August 22, 2025

Enrollment

ACTUAL participants

Conditions

Acute Respiratory Distress Syndrome (ARDS)

Interventions

ARDS patients

OTHER

Turning Ratios Into Prognosis: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Powerful Predictors of ARDS in Pediatric Burn Patients: A Prospective Evaluation

NCT07414056

Acute Respiratory Distress Syndrome (ARDS)

View study

RECRUITINGPHASE2

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

NCT06701669

Acute Respiratory Distress Syndrome (ARDS)ARDS+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 22, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Validation of a Semi-automatized Method to Detect Cyclic Hyperinflation on CT-scan in ARDS

Inclusion Criteria

Exclusion Criteria

Turning Ratios Into Prognosis: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Powerful Predictors of ARDS in Pediatric Burn Patients: A Prospective Evaluation

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury

A Trial of Staff Time With Proned Patients in the ICU Using the 'BathMat'

RecruitmEnt Assessed by eleCtRical Impedance Tomography

Clinical Evaluation of a Point of Care (POC) Assay to Identify Phenotypes in the Acute Respiratory Distress Syndrome